Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases
Aynur Pekcanlar Akay,1 Gamze Capa Kaya,2,3 Burak Baykara,1 Yusuf Demir,2,3 Handan Özek,1 Sevay Alsen,1 Mine Sencan Eren,2,3 Neslihan Inal Emiroglu,1 Turkan Ertay,2,3 Yesim Ozturk,4 Suha Miral,1 Hatice Durak,2,3 Evren Tufan4 1Department of Child and Adolescent Psychiatry, 2Department of Nucl...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/f221828e7b1948cd87d2468261364977 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:f221828e7b1948cd87d2468261364977 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:f221828e7b1948cd87d24682613649772021-12-02T08:05:00ZAtomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases1178-2021https://doaj.org/article/f221828e7b1948cd87d24682613649772015-11-01T00:00:00Zhttps://www.dovepress.com/atomoxetine-treatment-may-decrease-striatal-dopaminergic-transporter-a-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Aynur Pekcanlar Akay,1 Gamze Capa Kaya,2,3 Burak Baykara,1 Yusuf Demir,2,3 Handan Özek,1 Sevay Alsen,1 Mine Sencan Eren,2,3 Neslihan Inal Emiroglu,1 Turkan Ertay,2,3 Yesim Ozturk,4 Suha Miral,1 Hatice Durak,2,3 Evren Tufan4 1Department of Child and Adolescent Psychiatry, 2Department of Nuclear Medicine, 3Department of Pediatrics, Dokuz Eylul University Medical Faculty, Izmir, 4Department of Child and Adolescent Psychiatry, Abant İzzet Baysal University, Bolu, Turkey Abstract: Attention deficit/hyperactivity disorder is one of the most common neurodevelopmental disorders. The pathophysiology is thought to involve noradrenaline and dopamine. The role of dopamine transporter (DAT) was evaluated in imaging studies using mostly dopamine reuptake inhibitors. Atomoxetine is a selective noradrenaline reuptake inhibitor. Here we report the results of a pilot study conducted to evaluate changes in striatal DAT after 8 weeks of atomoxetine treatment. Our results suggest that 8 weeks of atomoxetine treatment may change striatal DAT bioavailability as measured via SPECT but that change was not correlated with genotype or clinical improvement. Keywords: neuroimaging, dopamine, noradrenaline, SLC6A3 protein, human, pragmatic clinical trial, pilot studyAkay APKaya GCBaykara BDemir YOzek HAlsen SEren MSEmiroglu NIErtay TOzturk YMiral SDurak HTufan EDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 2909-2912 (2015) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Akay AP Kaya GC Baykara B Demir Y Ozek H Alsen S Eren MS Emiroglu NI Ertay T Ozturk Y Miral S Durak H Tufan E Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases |
| description |
Aynur Pekcanlar Akay,1 Gamze Capa Kaya,2,3 Burak Baykara,1 Yusuf Demir,2,3 Handan Özek,1 Sevay Alsen,1 Mine Sencan Eren,2,3 Neslihan Inal Emiroglu,1 Turkan Ertay,2,3 Yesim Ozturk,4 Suha Miral,1 Hatice Durak,2,3 Evren Tufan4 1Department of Child and Adolescent Psychiatry, 2Department of Nuclear Medicine, 3Department of Pediatrics, Dokuz Eylul University Medical Faculty, Izmir, 4Department of Child and Adolescent Psychiatry, Abant İzzet Baysal University, Bolu, Turkey Abstract: Attention deficit/hyperactivity disorder is one of the most common neurodevelopmental disorders. The pathophysiology is thought to involve noradrenaline and dopamine. The role of dopamine transporter (DAT) was evaluated in imaging studies using mostly dopamine reuptake inhibitors. Atomoxetine is a selective noradrenaline reuptake inhibitor. Here we report the results of a pilot study conducted to evaluate changes in striatal DAT after 8 weeks of atomoxetine treatment. Our results suggest that 8 weeks of atomoxetine treatment may change striatal DAT bioavailability as measured via SPECT but that change was not correlated with genotype or clinical improvement. Keywords: neuroimaging, dopamine, noradrenaline, SLC6A3 protein, human, pragmatic clinical trial, pilot study |
| format |
article |
| author |
Akay AP Kaya GC Baykara B Demir Y Ozek H Alsen S Eren MS Emiroglu NI Ertay T Ozturk Y Miral S Durak H Tufan E |
| author_facet |
Akay AP Kaya GC Baykara B Demir Y Ozek H Alsen S Eren MS Emiroglu NI Ertay T Ozturk Y Miral S Durak H Tufan E |
| author_sort |
Akay AP |
| title |
Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases |
| title_short |
Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases |
| title_full |
Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases |
| title_fullStr |
Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases |
| title_full_unstemmed |
Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases |
| title_sort |
atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot spect report of three cases |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://doaj.org/article/f221828e7b1948cd87d2468261364977 |
| work_keys_str_mv |
AT akayap atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases AT kayagc atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases AT baykarab atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases AT demiry atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases AT ozekh atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases AT alsens atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases AT erenms atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases AT emirogluni atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases AT ertayt atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases AT ozturky atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases AT mirals atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases AT durakh atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases AT tufane atomoxetinetreatmentmaydecreasestriataldopaminergictransporteravailabilityafter8weekspilotspectreportofthreecases |
| _version_ |
1718398700029476864 |